A Phase I Trial of Vaccination With CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

The purpose of this study is to see if the investigator can help the immune system to work against myeloma.
This study will see if a vaccine made with altered dendritic cells will make T cells work against tumor cells. The stem cells collected for the transplant will also be used to grow dendritic cells in the lab. The dendritic cells will carry the antigens. These cells then will be injected under the skin. The investigators will do lab studies before and after the vaccination to find out if the vaccine is working.

开始日期2014-01-31

申办/合作机构

Memorial Sloan Kettering Cancer Center

100 项与 WT1 mRNA-electroporated Langerhans cells(Memorial Sloan Kettering Cancer Center) 相关的临床结果

登录后查看更多信息

100 项与 WT1 mRNA-electroporated Langerhans cells(Memorial Sloan Kettering Cancer Center) 相关的转化医学

登录后查看更多信息

100 项与 WT1 mRNA-electroporated Langerhans cells(Memorial Sloan Kettering Cancer Center) 相关的专利（医药）

登录后查看更多信息

项与 WT1 mRNA-electroporated Langerhans cells(Memorial Sloan Kettering Cancer Center) 相关的文献（医药）

2017-10-12·Blood1区 · 医学

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia

1区 · 医学

Article

作者: Cools, Nathalie ; Jorens, Philippe ; Anguille, Sébastien ; Van de Velde, Ann L. ; Couttenye, Marie M. ; Verlinden, Anke ; Gostick, Emma ; Vandenbosch, Irma ; Malfait, Ronald ; Van Driessche, Ann ; Lion, Eva ; Fujiki, Fumihiro ; Juliusson, Gunnar ; Oji, Yusuke ; Stein, Barbara ; Goossens, Herman ; Gadisseur, Alain P. ; Sugiyama, Haruo ; Nijs, Griet ; Maes, Marie-Berthe ; Vermeulen, Katrien ; Muylle, Ludo ; Ladell, Kristin ; Lammens, Martin ; Smits, Evelien L. ; Price, David A. ; Berneman, Zwi N. ; Deiteren, Kathleen ; Oka, Yoshihiro ; Schroyens, Wilfried A. ; Van Tendeloo, Viggo F.

Key Points:

WT1 mRNA-electroporated DCs can prevent or delay relapse in 43% of patients with AML in remission after chemotherapy. OS compares favorably with the new survival data from the Swedish Acute Leukemia Registry and correlates with molecular and WT1-specific CD8+ T-cell responses.

2013-12-01·Anticancer research

Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.

Article

作者: Vanderstraeten, Anke ; Coosemans, An ; Amant, Frédéric ; Tuyaerts, Sandra ; VAN Gool, Stefaan W ; Vergote, Ignace ; Verschuere, Tina ; Moerman, Philippe ; Berneman, Zwi N

AIM:

Treatment options are limited in uterine cancer, leading to a poor prognosis. Overexpression of Wilms' tumor gene 1 (WT1), the highest ranked tumor antigen, is attractive for immunotherapy.

PATIENTS AND METHODS:

Six pre-treated patients with uterine cancer received four weekly vaccines of autologous dendritic cells (DCs) electroporated with WT1 mRNA. Safety, feasibility and immunogenicity were assessed. In cases of response, patients received monthly booster vaccines.

RESULTS:

The technique was feasible. One patient had a local allergic reaction. Three out of four Human Leucocyte Antigen-A2 (HLA-A2)-positive patients showed an oncological response; an enrichment of WT1-specific T-cells was observed in two of them. Two HLA-A2-negative patients did not show an oncological or an immunological response.

CONCLUSION:

A first series of six patients with uterine cancer treated with WT1 mRNA-electroporated DCs is presented herein. Oncological and immunological responses were observed and are supportive for further research.

100 项与 WT1 mRNA-electroporated Langerhans cells(Memorial Sloan Kettering Cancer Center) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
多发性骨髓瘤	临床1期	美国	Memorial Sloan Kettering Cancer Center	2014-01-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01995708 (CTgov)	临床1期	多发性骨髓瘤	28	CT7, MAGE-A3,+WT1 mRNA-electroporated Langerhans cells ( LCs) (Arm 1 Vaccine)	衊膚膚壓鏇齋壓壓鹽鏇(夢範鹹鹹鏇築鏇憲鬱簾) = 餘簾鹽蓋遞願廠艱襯夢選觸構淵顧壓糧壓積糧 (窪鏇願選顧鏇醖築網簾, 積壓廠願餘憲憲選觸積 ~ 齋觸蓋廠築鏇獵齋淵製) 更多	-	2024-02-09
				Standard of care (Arm 2 Control)	衊膚膚壓鏇齋壓壓鹽鏇(夢範鹹鹹鏇築鏇憲鬱簾) = 網壓範繭淵鹹餘獵築憲選觸構淵顧壓糧壓積糧 (窪鏇願選顧鏇醖築網簾, 醖範範糧憲獵衊醖糧鏇 ~ 蓋憲製蓋築廠繭淵艱夢) 更多